Author/Editor		Zwitter, M; Kovač, V; Smrdel, U; Kocijančič, I
Title		Low-dose gemcitabine in long infusion and cisplatin for advanced NSCLC: a phase I - II trial
Type		članek
Source		In: Jassem J, editor. 9th central European lung cancer conference; 2004 Sep 23-25; Gdansk. Bologna: Medimond, Monduzzi editore, International proceedings division,
Publication year		2004
Volume		str. 145-8
Language		eng
Abstract		In a phase I-II trial, 61 patients (pts) with advanced non-small cell lung cancer (NSCLC) were treated with low-dose gemcitabine in long infusion and cisplatin. Treatment: on days 1 and 8 of a 3-weeks cycle, groups of 6 - 8 pts were given gemcitabine in 6-hours infusion at 130, 170 and 210 mg/m2; the remaining 40 pts received 250 mg/m2. On day 2, all patients received cisplatin at 75 mg/m2. Toxicity: 2 pts had grade 4 toxicity (cerebrovascular ischemia and arrythmia); additional 3 pts had grade 3 thromboembolic vascular events. Anemia was common: grade 2 in 34 pts and grade 3 in 4 pts. Most patients had reversible thrombocytosis and alopecia. Response to treatnzent: complete or partial response in 28/61 pts (46 %). Median survival is 9 months. Conclusion: This treatment has a distinct and acceptable toxicity and a remarkable response rate.
Descriptors		LUNG NEOPLASMS CARCINOMA, NON-SMALL-CELL LUNG CISPLATIN CLINICAL TRIALS, PHASE I CLINICAL TRIALS, PHASE II TREATMENT OUTCOME